Galen Report issue

For profit Phase 1 Phase 4
Founded: Craigavon Ireland (1968)
Status: Acquired by Warner Chilcott (2000) → now AbbVie (2019)

Organization Overview

First Clinical Trial
2010
NCT01176318
First Marketed Drug
1996
daunorubicin (cerubidine)
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Galen limited | Galen Limited | GALEN SPECIALTY | GALEN UK | GALEN (UK) | MILLICENT

Active Ingredients

Marketed Drugs (6)

daunorubicin (cerubidine) (1996)

estradiol (progynon depot) (2003)

lidocaine (xylocaine) (2005)

loxapine (loxitane) (2012)

prasterone (intrarosa) (2016)

tetracaine (pontocaine) (2005)

Drugs in Phase 4 Trials (1)

erdosteine (1 trial)

Drugs in Phase 1 Trials (3)

acetaminophen (tylenol) (1 trial)

codeine (Phenergan) (1 trial)

nefopam (Acupan) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lung Diseases (Phase 4)

Lung Diseases, Obstructive (Phase 4)

Pulmonary Disease, Chronic Obstructive (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 4